AstraZeneca (LSE: AZN) has announced the positive high-level results from the Phase III NEURO-TTRansform Phase III trial of eplontersen.
The British company is working with US RNA-targeted drug developer Ionis Pharmaceuticals (Nasdaq: IONS) to develop the candidate for people with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a rare disease.
The top-line results show the trial met both of its co-primary efficacy endpoints at a planned interim analysis after 35 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze